Every year almost 200 persons are diagnosed with oral cancer in Norway, and the number is increasing. The prognosis is poor with a 5-year survival rate of about 50%. The standard treatment is surgery, often combined with radiotherapy. The treatment often causes permanent side effects such as dry mouth, dental health problems, eating and speech problems, trismus, and dysphagia. The choice of treatment is mainly based on the size of the tumor as well as presence and extent of metastasis according to the TNM classification. However, there are large individual differences in response to treatment. Since the TNM system does not consider the heterogeneity in the biological properties of tumors, treatment choices that are based on the TNM classification cause over-treatment of some patients whereas others will receive less extensive treatment than they could benefit from. Biomarkers that can reflect the biological variations between the tumors have therefore been searched for a long time, but so far there are no such validated biomarkers.